As a result of the rise of generics and patent expirations
CPhI and P-MEC India, organised by UBM, returns to the Bombay Convention and Exhibition Centre, Mumbai (India) this week, from the 3–5 December.
The event returns with an increased scale, continuing its commitment to cater to all sectors of the pharma industry by co-locating with ICSE and BioPh India.
With the addition of Hall 7, P-MEC will host more exhibitors than previous years. Last year, 926 exhibitors were present and this is expected to rise to 1,000 this year to create the biggest show to date. Free online registration to attend CPhI and P-MEC India is now closed, however registration is still possible in Mumbai; the on-site fee is only INR500.
With a view to enhancing the visitor experience, CPhI India offers an enhanced mobile app for users of mobile communications devices with an Internet connection to help visitors navigate their way around the event, drive traffic to stands and stay up-to-date with schedules and speaker events.
India has increasingly become a focal point of the pharmaceutical industry and is now the third largest region in terms of volume. The country is fast becoming an innovation hub, increasingly matching Western standards, while also reducing the costs of manufacturing, showcasing the Indian pharma market's unique position and providing an optimum investment platform for international companies.
Outside the US, India has the highest number of FDA approved facilities (546), and the Indian pharma sector received USFDA approvals for around 40% of all Abbreviated New Drug Approvals (ANDA) during January to July 2013. Further, with R&D investments rapidly advancing, coupled with the rise in generics and supergenerics, India represents a key maturing market, with CPhI and P-MEC India facilitating opportunities to drive and enhance the sector.
Ahead of the event, the UBM India pharma awards took place on 2 December, celebrating the most innovative and dynamic areas across the Indian pharma community. Honouring companies who are driving forward industry changing initiatives, there were awards for multiple categories including: Product Development, Contract Research and Packaging Development. The evening also hosted a panel discussion entitled: 'Moving up the Global Pharma Value Chain’.
'The global pharmaceutical market has seen a significant shift over the last year, particularly as patent expirations are becoming more frequent and a potential patent cliff is shaking the industry,' said Chris Kilbee, UBM's Group Director, Pharma India.
'India, however, is thriving as the demand for generics is on the rise and companies are looking to drive down manufacturing costs. India is well positioned to accommodate increased demand, providing expertise in development and manufacturing. CPhI and P-MEC India will provide the ideal and essential platform for international and domestic suppliers and buyers to break into the market.'